Mansoor Mohammed has joined Combimatrix Molecular Diagnostics as its chief scientific officer and a member of its board of directors, CMDX said this week.
He most recently served as director of advanced technologies at Quest Diagnostics. Prior to working at Quest, Mohammed directed scientific R&D at Spectral Genomics.
Mohammed holds PhDs in molecular immunology and genetics from the University of Guelph in Ontario.
James Glynn is retiring from Invitrogen's board on April 21, the company said last week.
Glynn has served the company for almost 10 years and retires as chief executive emeritus.
Invitrogen said that there will be only nine directors after Glynn's departure.
GE Healthcare last week launched a EGFP-NFATc1 Translocation Assay using green fluorescent protein, which is used to screen compounds during drug discovery, the company said in a statement. The test evaluates the ability of compounds to bind and activate NFATc1 transcription factors in the cytoplasm, and it allows "temporal and spatial measurement of drug targets by quantifying real-time distribution" of GFP-tagged proteins, the company said.
The fully validated assay includes a "ready-to-use" optimized cell line and expression vector, and it is designed for optimal image acquisition and analysis on GE Healthcare's IN Cell Analysis System.
Finnzymes this week launched its Phusion Hot Start DNA Polymerase modified with an Affibody-based inactivation method that enhances the specificity of the polymerase, giving it fidelity and speed between 15-30 seconds per kilobase, as well as improved robustness, the company said in a statement. The polymerase has an error rate of 4.4 x 10-7, and it is capable of amplifying long segments, such as 7.5 kb genomic and 20 kb DNA, Finnzymes said.